维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="Giessmann T"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	Cut edges and surface characteristics produced by different microkeratomes显示文摘	Wilhelm FW Giessmann T Hanschke R	2000	J Refract Surg2000，16，6：	1
2	CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects显示文摘	Giessmann T Modess C Hecker U Zschiesche M Dazert P Kunert-Keil C	2004	Clin Pharmacol Ther2004，75，：	1
3	Oral bioavailability of digoxin is enhanced by talinolol:evidence for involvement of intestinal P-glycoprotein显示文摘	Weinbvenner A Giessmann T	2000	Clin Pharmacol Ther2000，6，1：	1
4	The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen显示文摘	Weitschies W Bernsdorf A Giessmann T	2005	Pharm Res2005，22，5：	1
5	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans 显示文摘	Giessmann T May K Modess C	2004	Clin Pharmacol Ther2004，76，3：	1
6	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP-2 and influences disposition of talinolol in humans显示文摘	Giessmann T May K Modess C	2004	Clin Pharmacol Ther2004，76，3：	1
7	The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen显示文摘	Weitschies W Bernsdorf A Giessmann T	2005	Pharm Res2005，22，5：	1
8	The oral, once- daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide 显示文摘	Hermann R Siegmund W Giessmann T	2007	J Clin Pharmacol2007，47，8：	1
9	Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging显示文摘	Schiller C P Frohlich T Giessmann W	2005	Aliment Pharmacol Ther2005，22，：	1
10	The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gutlumen显示文摘	Weitschies W Bernsdorf A Giessmann T	2005	Pharm Res2005，22，5：	1
11	The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen显示文摘	Bernsdorf A Giessmann T	2005	Pharm Res2005，22，5：	1
12	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and dis- position of the probe drug talinolol 显示文摘	Siegmund W Ludwig K Giessmann T	2002	Clin Pharmacol Ther2002，72，5：	1
13	Cut edges and surface characteristics produced by different microkeratomes 显示文摘	Wilhelm FW Giessmann T Hanschke R	2000	J Refract Surg2000，16，：	1
14	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein显示文摘	Westphal K Weinbrenner A Giessmann T	2000	Clin Pharrnacol Ther2000，68，：	1
15	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms显示文摘	Bernsdorf A Giessmann T Modess C	2006	Br J Clin Pharmacol2006，61，4：	1
16	Intesti- nal Quid volumes and transit of dosage forms as assessed by mag- netic resonance imaging显示文摘	SCHILLER C FORHLICH CP GIESSMANN T	2005	Aliment Pharmacol Ther2005，22，10：	1
17	Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein 显示文摘	Westphal K Weinbrenner A Giessmann T	2000	Clin Pharmacol Ther2000，68，1：	1
18	Oral bioavailability ofdigoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein 显示文摘	Westphal K Weinbrenner A Giessmann T	2000	Clin Pharmacol Ther2000，68，1：	1
19	The talinolol double-peak phenomenon is likely caused by presyst- emic processing after uptake from gut lumen显示文摘	WEITSCHIES W BERNSDORF A GIESSMANN T et (d	2005	Pharm Res2005，22，5：	1
20	Carbamaz-epine regulates intestinal P-glycoprotein and multi-drug resistance protein MRP2and influences dispo-sition of talinolol in humans显示文摘	Giessmann T May K Modess C	2004	Clin Pharmacol T-her2004，76，3：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示